Merck executes a “One Pipeline” diversification masterplan, tripling late-stage assets since 2021 to deliver 20+ potential blockbusters offsetting Keytruda’s $32.7B 2026 peak before 2028 LOE cliff. Strategic genius fuses subcutaneous Keytruda Qlex (38 tumor approvals), $10B Verona Pharma acquisition (Ohtuvayre COPD), and 80 Phase III trials across oncology (60% focus), cardiometabolic, immunology, vaccines, and hospital—targeting sustainable mid-single digit growth post-cliff.
Merck’s manufacturing scale and business development firepower secure external innovation at inflection points, while Winrevair ($1.4B 2025) and Capvaxive ($759M launch) validate execution velocity. The company forecasts $70B commercial opportunity by mid-2030s from recent launches and late-phase pipeline.
Oncology: Keytruda Qlex + ADC/Bispecific Reload
Commercial dominance persists through Keytruda ($31.7B 2025) subcutaneous Qlex formulation approved across 38 solid tumors, extending market share through faster administration despite 2028 exclusivity loss. Phase 3 oncology offensive advances MK-1084 (next-gen KRAS G12C), MK-5909 (bispecific T-cell engager), and subcutaneous PADCEV (enfortumab vedotin) Ph3 success. Strategic edge: Qlex subcutaneous preserves $7B+ 2032 revenue while ADC platform challenges AstraZeneca/Roche dominance.
Hospital/Anti-Infectives: Defenza + Next-Gen Portfolio
Defenza (pneumococcal 21-valent) captures $2B+ market share vs. Pfizer Prevnar, while MK-7110 doravirine/bevirimat HIV combo enters Ph3. Merck targets $5B hospital franchise through hospital-exclusive launches avoiding primary care competition.
Vaccines: Capvaxive + Gardasil Sustainment
Capvaxive ($759M Q4 2025 launch) establishes $3B peak trajectory despite Gardasil 39% decline from China restrictions. Merck advances pneumococcal combos and influenza assets maintaining $8B+ stablecoin revenue base.
Cardiometabolic: Winrevair + Emerging Pipeline
Winrevair (sotatercept) pulmonary arterial hypertension treatment generated $1.4B 2025 sales with $3B peak potential, while enlicitide decanoate oral PCSK9 inhibitor demonstrates Phase 3 LDL-C reductions. Underground strategy: Verona’s Ohtuvayre COPD acquisition ($10B deal) adds $10B market opportunity through first novel inhaled mechanism in 20 years.
Immunology: Early-Stage Blockbuster Bets
Merck advances milvexian Factor XIa inhibitor (Ph3 stroke prevention) and bomachadenosyn (oral TYK2 inhibitor psoriasis). Strategic positioning: Non-oncology diversification reduces Keytruda dependency from 50% to 30% revenue exposure.
| Therapeutic Area | Commercial Anchor | Phase 3 Priority | 2026 Catalyst | Peak Sales | Strategic Moat |
|---|---|---|---|---|---|
| Oncology | Keytruda Qlex | MK-1084 KRAS | Filing H2 2026 | $7B+ post-LOE | Subcutaneous conversion |
| Hospital | Defenza | MK-7110 HIV | Ph3 readout | $5B | Hospital exclusivity |
| Vaccines | Capvaxive | Pneumococcal combo | Launch | $3B | Manufacturing scale |
| PAH | Winrevair | Label expansion | H1 2026 | $3B | First-in-class |
| COPD | Ohtuvayre | Market expansion | 2027 peak | $3-5B | Novel mechanism |
Execution Alpha: Verona integration accelerates non-oncology revenue while Keytruda Qlex softens 70% cliff impact. Merck trades at attractive valuation versus oncology peers—2026 Winrevair expansions and ADC readouts catalyze $70B trajectory execution.
By
